Is Agomab Therapeutics NV (AGMB) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.2% / 30% | 25.8% / 30% | 0.3% / 30% | N/A | ✓ HALAL |
| DJIM | 0.2% / 33% | 25.8% / 33% | 0.3% / 33% | N/A | ✓ HALAL |
| MSCI | 0.7% / 33% | 83.1% / 33% | 1.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.2% / 33% | 25.8% / 33% | 0.3% / 33% | N/A | ✓ HALAL |
| FTSE | 0.7% / 33% | 83.1% / 33% | 1.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$47M |
| Free Cash Flow | -$48M |
| Total Debt | $2M |
| Debt-to-Equity | 0.8 |
| Current Ratio | 14.0 |
| Total Assets | $206M |
Price & Trading
| Last Close | $11.87 |
| 50-Day MA | $14.39 |
| 200-Day MA | $14.39 |
| Avg Volume | 230K |
|
52-Week Range
$10.50
| |
About Agomab Therapeutics NV (AGMB)
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases with a focus on chronic fibrotic indications with unmet medical needs. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Agomab Therapeutics NV (AGMB) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Agomab Therapeutics NV is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Agomab Therapeutics NV's debt ratio?
Agomab Therapeutics NV's debt ratio is 0.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.7%.
What are Agomab Therapeutics NV's key financial metrics?
Agomab Therapeutics NV has a market capitalization of $534M.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.